The orosomucoid 1 protein (α1 acid glycoprotein) is overexpressed in odontogenic myxoma

Proteome Science

Guillermo Mendoza-Hernández³  Carlos Licéaga-Escalera⁴  Juan J Trujillo⁴  J Eduardo Farfán-Morales⁵  Fidel C Hernández-Hernández¹  Febe E Cázares-Raga¹  Ronell Bologna-Molina²  Mario A Rodríguez¹  Alejandro García-Muñoz¹ 

[1] Departamento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México;Facultad de Odontología, Universidad de la República (UDELAR), Montevideo, Uruguay;Departamento de Bioquímica, Facultad de Medicina, UNAM, México, D.F., México;Departamento de Cirugía Maxilofacial, Hospital Juárez de México, México, D.F., México;Laboratorio de Patología Molecular, Instituto Nacional de Pediatría, México, D.F., México

关键词: α1 acid glycoprotein;    Orosomucoid 1;    Proteomic analysis;    Dental follicle;    Odontogenic myxoma;   

Others  :  817214
DOI  :  10.1186/1477-5956-10-49

 received in 2012-02-07, accepted in 2012-08-03,  发布年份 2012

【 摘 要 】

Background

Odontogenic myxoma (OM) is a benign, but locally invasive, neoplasm occurring in the jaws. However, the molecules implicated in its development are unknown. OM as well as Dental Follicle (DF), an odontogenic tissue surrounding the enamel organ, is derived from ectomesenchymal/mesencyhmal elements. To identify some protein that could participate in the development of this neoplasm, total proteins from OM were separated by two-dimensional electrophoresis and the profiles were compared with those obtained from DF, used as a control.

Results

We identified eight proteins with differential expression; two of them were downregulated and six upregulated in OM. A spot consistently overexpressed in odontogenic myxoma, with a molecular weight of 44-kDa and a pI of 3.5 was identified as the orosomucoid 1 protein. Western blot experiments confirmed the overexpression of this protein in odontogenic myxoma and immunohistochemical assays showed that this protein was mainly located in the cytoplasm of stellate and spindle-shaped cells of this neoplasm.

Conclusion

Orosomucoid 1, which belongs to a group of acute-phase proteins, may play a role in the modulation of the immune system and possibly it influences the development of OM.

【 授权许可】

   
2012 Garcia-Muñoz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Buchner A, Odell E: Odontogenic myxoma/myxofibroma. In Head and neck tumours Pathology and genetics WHO Classification of tumours. Edited by Barnes L, Eveson J, Reichart P, Sidransky D. IARC Press, Lyon; 2005:316.
• [2]Boffano P, Gallesio C, Barreca A, Bianchi FA, Garzino-Demo P, Roccia F: Surgical treatment of odontogenic myxoma. J Craniofac Surg 2011, 22:982-987.
• [3]Huang GT, Gronthos S, Shi S: Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res 2009, 88:792-806.
• [4]Suarez PA, Batsakis JG, El-Naggar AK: Don't confuse dental soft tissues with odontogenic tumors. Ann Otol Rhinol Laryngol 1996, 105:490-494.
• [5]Muller H, Slootweg PJ: A peculiar complication in Le Fort I osteotomy. J Craniomaxillofac Surg 1988, 16:238-239.
• [6]Kim J, Ellis GL: Dental follicular tissue: misinterpretation as odontogenic tumors. J Oral Maxillofac Surg 1993, 51:762-767. discussion 767–768
• [7]Lombardi T, Lock C, Samson J, Odell EW: S100, alpha-smooth muscle actin and cytokeratin 19 immunohistochemistry in odontogenic and soft tissue myxomas. J Clin Pathol 1995, 48:759-762.
• [8]Lombardi T, Samson J, Bernard JP, Di Felice R, Fiore-Donno G, Muhlhauser J, Maggiano N: Comparative immunohistochemical analysis between jaw myxoma and mesenchymal cells of tooth germ. Pathol Res Pract 1992, 188:141-144.
• [9]Mosqueda-Taylor A: New findings and controversies in odontogenic tumors. Med Oral Patol Oral Cir Bucal 2008, 13:E555-E558.
• [10]Bast BT, Pogrel MA, Regezi JA: The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. J Oral Maxillofac Surg 2003, 61:1463-1466.
• [11]Martinez-Mata G, Mosqueda-Taylor A, Carlos-Bregni R, de Almeida OP, Contreras-Vidaurre E, Vargas PA, Cano-Valdez AM, Dominguez-Malagon H: Odontogenic myxoma: clinico-pathological, immunohistochemical and ultrastructural findings of a multicentric series. Oral Oncol 2008, 44:601-607.
• [12]Iezzi G, Piattelli A, Rubini C, Artese L, Fioroni M, Carinci F: MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolaryngol Ital 2007, 27:237-242.
• [13]Curran AE, Damm DD, Drummond JF: Pathologically significant pericoronal lesions in adults: Histopathologic evaluation. J Oral Maxillofac Surg 2002, 60:613-617. discussion 618
• [14]Kotrashetti VS, Kale AD, Bhalaerao SS, Hallikeremath SR: Histopathologic changes in soft tissue associated with radiographically normal impacted third molars. Indian J Dent Res 2010, 21:385-390.
• [15]Graham DR, Elliott ST, Van Eyk JE: Broad-based proteomic strategies: a practical guide to proteomics and functional screening. J Physiol 2005, 563:1-9.
• [16]Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergun S: Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5:4296-4304.
• [17]Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L: Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers 2011, 26:262-273.
• [18]Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008, 14:6246-6252.
• [19]Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, et al.: Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011, 20:289-299.
• [20]Schneider LC, Weisinger E: Odontogenic fibromyxoma arising from the periodontal ligament. J Periodontol 1975, 46:493-497.
• [21]Lucas R, Pindborg J: Odontogenic tumors and tumor-like lesions. Scientific foundations of dentistry, London; 1976.
• [22]Adekeye EO, Avery BS, Edwards MB, Williams HK: Advanced central myxoma of the jaws in Nigeria. Clinical features, treatment and pathogenesis. Int J Oral Surg 1984, 13:177-186.
• [23]Moshiri S, Oda D, Worthington P, Myall R: Odontogenic myxoma: histochemical and ultrastructural study. J Oral Pathol Med 1992, 21:401-403.
• [24]Hasleton PS, Simpson W, Craig RD: Myxoma of the mandible–a fibroblastic tumor. Oral Surg Oral Med Oral Pathol 1978, 46:396-406.
• [25]Schmidt-Westhausen A, Becker J, Schuppan D, Burkhardt A, Reichart PA: Odontogenic myxoma–characterisation of the extracellular matrix (ECM) of the tumour stroma. Eur J Cancer B Oral Oncol 1994, 30B:377-380.
• [26]Slootweg PJ, van den Bos T, Straks W: Glycosaminoglycans in myxoma of the jaw: a biochemical study. J Oral Pathol 1985, 14:299-306.
• [27]Supuran CT: Carbonic anhydrases–an overview. Curr Pharm Des 2008, 14:603-614.
• [28]Noffke CE, Raubenheimer EJ, Chabikuli NJ, Bouckaert MM: Odontogenic myxoma: review of the literature and report of 30 cases from South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 104:101-109.
• [29]Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600.
• [30]Karius T, Schnekenburger M, Ghelfi J, Walter J, Dicato M, Diederich M: Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell lines. Biochem Pharmacol 2011, 81:1329-1342.
• [31]Harada T, Kuramitsu Y, Makino A, Fujimoto M, Iizuka N, Hoshii Y, Takashima M, Tamesa M, Nishimura T, Takeda S, et al.: Expression of tropomyosin alpha 4 chain is increased in esophageal squamous cell carcinoma as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Proteomics Clin Appl 2007, 1:215-223.
• [32]Fu Y, Lee AS: Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 2006, 5:741-744.
• [33]Koumenis C, Wouters BG: "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 2006, 4:423-436.
• [34]Morrison DK: The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009, 19:16-23.
• [35]Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H: 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol 2011, 22:705-712.
• [36]Tardif JC, Heinonen T, Noble S: High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep 2009, 11:58-63.
• [37]Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-4596.
• [38]Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006, 12:1536-1544.
• [39]Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H: Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34:205-214.
• [40]Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, Mogg M, Schreiber M, Feuerstein I, Huck CW, et al.: Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27:1641-1650.
• [41]Marchi N, Mazzone P, Fazio V, Mekhail T, Masaryk T, Janigro D: ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 2008, 112:1313-1324.
• [42]van Gool J, van Vugt H, Helle M, Aarden LA: The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol 1990, 57:200-210.
• [43]Stanciu L, Dumitrascu D, Radu D, Badea R: Non-specific tumoral markers in hepatocellular carcinoma. Med Interne 1990, 28:139-144.
• [44]Tosner J, Krejsek J, Louda B: Serum prealbumin, transferrin and alpha-1-acid glycoprotein in patients with gynecological carcinomas. Neoplasma 1988, 35:403-411.
• [45]Croce MV, Price MR, Segal-Eiras A: Association of a alpha1 acidic glycoprotein and squamous cell carcinoma of the head and neck. Pathol Oncol Res 2001, 7:111-117.
• [46]Croce MV, Segal-Eiras A: Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. Cancer Invest 1996, 14:421-426.
• [47]Sorensson J, Matejka GL, Ohlson M, Haraldsson B: Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol 1999, 276:H530-H534.
• [48]Gahmberg CG, Andersson LC: Leukocyte surface origin of human alpha1-acid glycoprotein (orosomucoid). J Exp Med 1978, 148:507-521.
• [49]Andersson LC, Gahmberg CG: Surface glycoproteins of resting and activated human T lymphocytes. Mol Cell Biochem 1979, 27:117-131.
• [50]Irmak S, Oliveira-Ferrer L, Singer BB, Ergun S, Tilki D: Pro-angiogenic properties of orosomucoid (ORM). Exp Cell Res 2009, 315:3201-3209.
• [51]Fournier T, Medjoubi NN, Porquet D: Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482:157-171.
• [52]Lee SY, Lim JW, Kim YM: Effect of alpha1-acid glycoprotein expressed in cancer cells on malignant characteristics. Mol Cells 2001, 11:341-345.
• [53]Lopez-Vidriero MT, Reid L: Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases. Am Rev Respir Dis 1978, 117:465-477.
• [54]Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21:1037-1053.
• [55]Perez E, Gallegos JL, Cortes L, Calderon KG, Luna JC, Cazares FE, Velasquillo MC, Kouri JB, Hernandez FC: Identification of latexin by a proteomic analysis in rat normal articular cartilage. Proteome Sci 2010, 8:27. BioMed Central Full Text
• [56]Zimny-Arndt U, Schmid M, Ackermann R, Jungblut PR: Classical proteomics: two-dimensional electrophoresis/MALDI mass spectrometry. Methods Mol Biol 2009, 492:65-91.
• [57]Lau AT, He QY, Chiu JF: A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem J 2004, 382:641-650.